Invention Grant
US07897729B2 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors
有权
靶向低亲和力Fcγ受体的聚合免疫球蛋白融合蛋白
- Patent Title: Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors
- Patent Title (中): 靶向低亲和力Fcγ受体的聚合免疫球蛋白融合蛋白
-
Application No.: US12212776Application Date: 2008-09-18
-
Publication No.: US07897729B2Publication Date: 2011-03-01
- Inventor: Barry G. W. Arnason , Mark A. Jensen , David M. White
- Applicant: Barry G. W. Arnason , Mark A. Jensen , David M. White
- Applicant Address: US IL Chicago
- Assignee: Iterative Therapeutics, Inc.
- Current Assignee: Iterative Therapeutics, Inc.
- Current Assignee Address: US IL Chicago
- Agency: Stipkala LLC
- Agent Harry J. Guttman
- Main IPC: C07K16/00
- IPC: C07K16/00

Abstract:
The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.
Public/Granted literature
- US20090117133A1 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS Public/Granted day:2009-05-07
Information query